Cadrenal Therapeutics (NASDAQ:CVKD) Given New $32.00 Price Target at HC Wainwright

Cadrenal Therapeutics (NASDAQ:CVKD) had its target price lifted by HC Wainwright from $3.00 to $32.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ CVKD opened at $17.90 on Monday. The company has a market capitalization of $19.12 million, a price-to-earnings ratio of -2.68 and a beta of 1.52. Cadrenal Therapeutics has a 1-year low of $5.40 and a 1-year high of $32.55. The business’s 50 day moving average price is $13.09.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.